GLAESNER, WOLFGANG,MILLICAN, ROHN LEE JR.,VICK, ANDREW MARK
申请号：
CA2528591
公开号：
CA2528591C
申请日:
2004.06.10
申请国别(地区):
CA
年份:
2013
代理人:
摘要：
The invention provides specific GLP-1 analogs fused to specific IgG4-Fcderivatives. These fusion proteins have an increased half-life, decreasedimmunogenicity, and reduce effector activity. The fusion proteins are usefulin treating diabetes, obesity, irritable bowel syndrome and other conditionsthat would be benefited by lowering plasma glucose, inhibiting gastric and/orintestinal motility and inhibiting gastric and/or intestinal emptying, orinhibiting food intake.
